Latest news with #QuarterlyReports
Yahoo
29-05-2025
- Business
- Yahoo
The St. Joe Company Announces Plans for a Publix Super Market at Watersound® West Bay Center Along With Additional Leasable Commercial Space
PANAMA CITY BEACH, Fla., May 29, 2025--(BUSINESS WIRE)--The St. Joe Company (NYSE: JOE) ("St. Joe") announces plans for construction of a Publix Super Market ("Publix") at Watersound West Bay Center located at the entrance to the Latitude Margaritaville® Watersound community. The new Publix, planned for approximately 50,000 square feet, including a pharmacy, deli, bakery and an adjacent liquor store, is anticipated to break ground later this year. "Publix at Watersound West Bay Center will provide customers with a convenient location, minutes from area beaches, an international airport and a new medical campus," said Hannah Herring, Publix Media Relations Manager. "We are excited to see construction begin, and we look forward to being a part of Watersound West Bay Center and the continued growth of the region." In addition to Publix, plans call for adjacent in-line space as well as a standalone, multi-tenant building. The multi-tenant building is currently under construction and available to lease for anticipated occupancy in early 2026. Watersound West Bay Center is conveniently located to serve the fast-growing State Road 79 corridor and is planned for approximately 500,000 square feet of commercial space in an open-air, pedestrian-friendly shopping and dining destination for residents and visitors alike. "Residents of the Latitude Margaritaville Watersound community are thrilled to welcome a grocer and commercial options to their growing community," said William Brock, Vice President of Commercial Real Estate for St. Joe. "We are proud to bring to Watersound West Bay Center a quality brand like Publix along with plans to create leasable spaces for local, regional and national companies. With much anticipated growth along the State Road 79 corridor, this center will be a great addition to the region for both residents and visitors." For more information about leasing opportunities, please call 888-836-8353 or email lease@ Click here for a comprehensive video tour of all St. Joe's commercial assets or visit for more information. Important Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements," within the meaning of Section 21E of the Exchange Act, including statements regarding the proposed Watersound West Bay Center, and Publix Super Market. These forward-looking statements are qualified in their entirety by cautionary statements and risk factors set forth in St. Joe's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, its Quarterly Reports on Form 10-Q and subsequent current reports on Form 8-K, as well as the following: (1) the ability of St. Joe to complete Watersound West Bay Center, the building for Publix and a multi-tenant building and (2) the interest of prospective customers and tenants in a Publix Super Market, multi-tenant building and Watersound West Bay Center. About the St. Joe Company The St. Joe Company ("Company") is a diversified real estate development, asset management and operating company with real estate assets and operations in Northwest Florida. The Company intends to use existing assets for residential, hospitality and commercial ventures and has significant residential and commercial land-use entitlements. The Company actively seeks higher and better uses for its real estate assets through a range of development activities. More information about the Company can be found on its website at ©2025 The St Joe Company. "St. Joe®," "JOE®," the "Taking Flight" Design®," "St. Joe (and Taking Flight Design)®" and "Watersound®" are registered service marks of The St. Joe Company. Latitude Margaritaville® is a trademark of Margaritaville Enterprises, LLC and used under license. View source version on Contacts Media Contacts The St. Joe Company, Investor RelationsMarek The St. Joe Company, Media RelationsMary Beth Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Global Medical REIT Inc. Board Declares 2025 Second Quarter Common and Preferred Dividends
BETHESDA, Md., May 28, 2025--(BUSINESS WIRE)--Global Medical REIT Inc. (NYSE: GMRE) (the "Company" or "GMRE"), a net-lease medical real estate investment trust (REIT) that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, announced today that its Board of Directors ("Board") has declared the Company's 2025 second quarter common and preferred dividends. Common Dividend The Board has declared the Company's 2025 second quarter cash dividend of $0.15 per share of common stock and unit, which is payable on July 9, 2025 to common stockholders and unitholders of record as of June 20, 2025. The Company has prepared an updated investor presentation which contains certain information about the dividend that is available at on the "Investor Relations" page. Series A Preferred Dividend The Board has also declared a quarterly cash dividend of $0.46875 per share on its Series A Cumulative Redeemable Preferred Stock, $0.001 par value per share (the "Series A Preferred Stock"), which is payable on July 31, 2025, to Series A Preferred stockholders of record as of July 15, 2025. This represents the Company's quarterly dividend on its Series A Preferred Stock for the period from April 30, 2025 through July 30, 2025. About Global Medical REIT Inc. Global Medical REIT Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. Additional information on GMRE can be obtained on its website at Forward-Looking Statements Certain statements contained herein may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company's intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company's forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement. View source version on Contacts Investors: Stephen (203) 682-8377 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
27-05-2025
- Business
- Reuters
New Fortress Energy discloses notice from Nasdaq
May 27 (Reuters) - U.S. LNG company New Fortress Energy (NFE.O), opens new tab on Tuesday said it received a notice from Nasdaq on non-compliance with the stock market's listing rule for not submitting its quarterly reports with the U.S. Securities and Exchange Commission.
Yahoo
15-05-2025
- Business
- Yahoo
Retractable Technologies, Inc. Results for the Period Ended March 31, 2025
LITTLE ELM, Texas, May 15, 2025--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $8.3 million for the first three months of 2025 and an operating loss of $4.7 million for the period, as compared to total net sales for the same period last year of $7.6 million and an operating loss of nearly $3.0 million. The differences in operating losses are largely due to an increase in tariffs and additional period costs related to increased domestic production activities. Tariffs are expected to continue to materially increase costs in future periods despite recent reductions in some tariff rates. Retractable reduced its dependence on its Chinese manufacturers in the first quarter of 2025 to 62.7% from 90.4% in the first quarter of 2024 by increasing domestic manufacturing. Retractable has hired additional manufacturing personnel while reducing its workforce in April 2025 in other departments, such as general and administrative personnel. Retractable has adapted certain equipment to enable additional domestic manufacturing and expects to adapt additional equipment for the same purpose over the next few months. Unrealized losses on investments were a significant factor in the computation of net income for the first quarter of 2025. Retractable experienced significant growth in late 2020 through early 2022 due to material orders from the U.S. government to supply syringes for COVID-19 vaccination efforts. Such orders included payment for certain freight charges as well. As a result, comparability to revenues and expenses in recent years may be challenging. Below are first quarter revenue figures from 2018 – 2025, as obtained from Retractable's Quarterly Reports on Form 10-Q as filed with the U.S Securities and Exchange Commission. Three Months Ended March 31, (Amounts in millions) 2025 2024 2023 2022 2021 2020 2019 2018 U.S. sales (excluding U.S. government) $ 7.4 $ 6.6 $ 5.4 $ 10.2 $ 11.0 $ 8.3 $ 6.1 $ 6.6 Sales to U.S. government — — — 15.7 37.8 — — — North and South America sales (excluding U.S.) 0.6 0.2 4.8 11.1 0.9 2.8 1.3 1.0 Other international sales 0.3 0.8 0.8 7.7 0.4 0.1 0.5 0.1 Total sales $ 8.3 $ 7.6 $ 11.0 $ 44.7 $ 50.1 $ 11.2 $ 7.9 $ 7.7 Retractable reports the following results of operations for the three months ended March 31, 2025 and 2024, respectively. Further details concerning the results of operations, as well as other matters, are available in Retractable's Form 10-Q filed on May 15, 2025 with the U.S Securities and Exchange Commission. Comparison of Three Months Ended March 31, 2025 and March 31, 2024 Domestic sales accounted for 89.6% and 87.4% of total revenues for the three months ended March 31, 2025 and 2024, respectively. Domestic revenues increased 11.9%, while domestic unit sales increased 17.2%. Domestic unit sales represented 84.9% of total unit sales for the three months ended March 31, 2025. The increase in unit sales did not translate into a proportional increase in domestic revenues, primarily due to a decrease in average selling price, which was largely impacted by higher transaction costs associated with distributor agreements. International revenues for the three months ended March 31, 2025 remained consistent compared to the same period in 2024. However, average selling price per unit declined relative to the first quarter of 2024, primarily due to a shift in product mix. International sales for the three months ended March 31, 2024 included a higher proportion of premium-priced Blood Collection Sets and Easy Point Needles, which typically yield higher average selling price. There remains uncertainty regarding the timing of future international orders. Overall, units sales increased 18.9%. Cost of manufactured product increased 50.3% principally due to an increase in tariffs and additional period costs related to increased domestic production activities. Royalty expense increased 8.8% primarily due to the increase in gross sales, slightly offset by a decrease in royalties received from sublicenses. Tariffs are expected to continue to materially increase our costs in future periods. Approximately $1.5 million was spent on tariff expenses in the first quarter of 2025. These costs are included in Cost of manufactured product. Operating expenses decreased 4.3%. The decrease was primarily driven by lower legal and litigation fees, as well as a reduction in outside accounting fees. The loss from operations was $4.7 million compared to a loss of approximately $3 million for the same period last year. The increased loss was due to lower gross profit for the current period. The unrealized loss on debt and equity securities was $7.2 million due to the decreased market values of those securities. The provision for income taxes was $286 thousand as compared to a provision for income taxes of $86 thousand for the same period in 2024. The difference is primarily related to fully reserving the deferred tax asset in the second quarter of 2024. ABOUT RETRACTABLE Retractable manufactures and markets VanishPoint® and Patient Safe® safety medical products and the EasyPoint® needle. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors. For more information on Retractable, visit its website at Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements. Factors that could cause or contribute to such differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission. View source version on Contacts Retractable Technologies, W. Fort III, 888-806-2626 or 972-294-1010Vice President, Chief Financial Officer, and Chief Accounting Officer Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-05-2025
- Business
- Business Wire
Retractable Technologies, Inc. Results for the Period Ended March 31, 2025
LITTLE ELM, Texas--(BUSINESS WIRE)--Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $8.3 million for the first three months of 2025 and an operating loss of $4.7 million for the period, as compared to total net sales for the same period last year of $7.6 million and an operating loss of nearly $3.0 million. The differences in operating losses are largely due to an increase in tariffs and additional period costs related to increased domestic production activities. Tariffs are expected to continue to materially increase costs in future periods despite recent reductions in some tariff rates. Retractable reduced its dependence on its Chinese manufacturers in the first quarter of 2025 to 62.7% from 90.4% in the first quarter of 2024 by increasing domestic manufacturing. Retractable has hired additional manufacturing personnel while reducing its workforce in April 2025 in other departments, such as general and administrative personnel. Retractable has adapted certain equipment to enable additional domestic manufacturing and expects to adapt additional equipment for the same purpose over the next few months. Unrealized losses on investments were a significant factor in the computation of net income for the first quarter of 2025. Retractable experienced significant growth in late 2020 through early 2022 due to material orders from the U.S. government to supply syringes for COVID-19 vaccination efforts. Such orders included payment for certain freight charges as well. As a result, comparability to revenues and expenses in recent years may be challenging. Below are first quarter revenue figures from 2018 – 2025, as obtained from Retractable's Quarterly Reports on Form 10-Q as filed with the U.S Securities and Exchange Commission. Retractable reports the following results of operations for the three months ended March 31, 2025 and 2024, respectively. Further details concerning the results of operations, as well as other matters, are available in Retractable's Form 10-Q filed on May 15, 2025 with the U.S Securities and Exchange Commission. Comparison of Three Months Ended March 31, 2025 and March 31, 2024 Domestic sales accounted for 89.6% and 87.4% of total revenues for the three months ended March 31, 2025 and 2024, respectively. Domestic revenues increased 11.9%, while domestic unit sales increased 17.2%. Domestic unit sales represented 84.9% of total unit sales for the three months ended March 31, 2025. The increase in unit sales did not translate into a proportional increase in domestic revenues, primarily due to a decrease in average selling price, which was largely impacted by higher transaction costs associated with distributor agreements. International revenues for the three months ended March 31, 2025 remained consistent compared to the same period in 2024. However, average selling price per unit declined relative to the first quarter of 2024, primarily due to a shift in product mix. International sales for the three months ended March 31, 2024 included a higher proportion of premium-priced Blood Collection Sets and Easy Point Needles, which typically yield higher average selling price. There remains uncertainty regarding the timing of future international orders. Overall, units sales increased 18.9%. Cost of manufactured product increased 50.3% principally due to an increase in tariffs and additional period costs related to increased domestic production activities. Royalty expense increased 8.8% primarily due to the increase in gross sales, slightly offset by a decrease in royalties received from sublicenses. Tariffs are expected to continue to materially increase our costs in future periods. Approximately $1.5 million was spent on tariff expenses in the first quarter of 2025. These costs are included in Cost of manufactured product. Operating expenses decreased 4.3%. The decrease was primarily driven by lower legal and litigation fees, as well as a reduction in outside accounting fees. The loss from operations was $4.7 million compared to a loss of approximately $3 million for the same period last year. The increased loss was due to lower gross profit for the current period. The unrealized loss on debt and equity securities was $7.2 million due to the decreased market values of those securities. The provision for income taxes was $286 thousand as compared to a provision for income taxes of $86 thousand for the same period in 2024. The difference is primarily related to fully reserving the deferred tax asset in the second quarter of 2024. ABOUT RETRACTABLE Retractable manufactures and markets VanishPoint ® and Patient Safe ® safety medical products and the EasyPoint ® needle. The VanishPoint ® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe ® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint ® is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint ® needle also can be used to aspirate fluids and for blood collection. Retractable's products are distributed by various specialty and general line distributors. For more information on Retractable, visit its website at Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect Retractable's current views with respect to future events. Retractable believes that the expectations reflected in such forward-looking statements are accurate. However, Retractable cannot assure you that such expectations will materialize. Actual future performance could differ materially from such statements. Factors that could cause or contribute to such differences include, but are not limited to: tariffs; material changes in demand; Retractable's ability to maintain liquidity; Retractable's maintenance of patent protection; Retractable's ability to maintain favorable third party manufacturing and supplier arrangements and relationships; foreign trade risk; Retractable's ability to access the market; production costs; the impact of larger market players in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in Retractable's periodic reports filed with the U.S. Securities and Exchange Commission.
